RAMM Pharma Corp.
RAMM
CNSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -77.94% | -41.64% | -27.13% | -28.92% | 0.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -77.94% | -41.64% | -27.13% | -28.92% | 0.47% |
| Cost of Revenue | -89.78% | -73.89% | 49.94% | -12.45% | 6.11% |
| Gross Profit | -36.07% | -10.74% | -99.93% | -62.15% | -15.46% |
| SG&A Expenses | -22.00% | -56.20% | -42.30% | -56.29% | -20.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -70.27% | -35.80% | -26.67% | -21.21% | -43.08% |
| Total Operating Expenses | -46.02% | -57.59% | -17.92% | -44.65% | -12.79% |
| Operating Income | 19.63% | 61.76% | 6.98% | 54.85% | 21.37% |
| Income Before Tax | 28.52% | 38.72% | 47.54% | 93.75% | 53.91% |
| Income Tax Expenses | -- | 30.51% | -- | -- | -- |
| Earnings from Continuing Operations | 22.28% | 38.67% | 47.54% | 88.58% | 57.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.28% | 38.67% | 47.54% | 88.58% | 57.61% |
| EBIT | 19.63% | 61.76% | 6.98% | 54.85% | 21.37% |
| EBITDA | 11.04% | 63.93% | -14.19% | 56.92% | 20.07% |
| EPS Basic | 21.67% | 38.64% | 47.54% | 88.79% | 57.75% |
| Normalized Basic EPS | 7.32% | 34.67% | 44.74% | 65.67% | 31.67% |
| EPS Diluted | 21.67% | 38.64% | 47.54% | 88.79% | 57.75% |
| Normalized Diluted EPS | 7.32% | 34.67% | 44.74% | 65.67% | 31.67% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |